^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Torisel (temsirolimus) (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer
Published date:
04/15/2015
Excerpt:
Patients with mesenchymal/MpBC treated with temsirolimus-based regimens were evaluated...Of the eight patients who achieved SD ≥6 months/CR/PR, all 4 patients with available tissue had a molecular aberration that activate the PIK3CA/Akt/mTOR axis: PIK3CA mutation = 2; PTEN loss = 1; NF2 aberration = 1.
Secondary therapy:
pegylated liposomal doxorubicin
DOI:
10.1093/annonc/mdv163
